Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 11/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.78 |
| ▸ | MAPT | P10636 | 8/20 | 0.78 |
| ▸ | TP53 | P04637 | 7/20 | 0.78 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.78 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.78 |
| ▸ | ALOX12 | P18054 | 5/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.78 |
| ▸ | RECQL | P46063 | 3/20 | 0.78 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.78 |
| ▸ | CDK2 | P24941 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | PKM | P14618 | 2/20 | 0.73 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.73 |
| ▸ | CA12 | O43570 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15676575 | 0.88 | MEN1 (1.00) | MEN1KMT2AKDM4ECYP3A4MAPT | |
| SCHEMBL30626973 | 0.88 | MEN1 (1.00) | MEN1KMT2AKDM4ECYP3A4MAPT | |
| SCHEMBL29437764 | 0.88 | MEN1 (1.00) | MEN1KMT2AKDM4ECYP3A4MAPT | |
| SCHEMBL169366 | 0.88 | MEN1 (1.00) | MEN1KMT2AKDM4ECYP3A4MAPT | |
| SCHEMBL2746872 | 0.86 | MEN1 (0.90) | MEN1KMT2AKDM4ECYP3A4MAPT | |
| SCHEMBL27451564 | 0.86 | MEN1 (0.97) | MEN1KMT2AKDM4ECYP3A4MAPT | |
| Myricetin SCHEMBL2278240 | 0.85 | MEN1 (0.77) | MEN1KMT2AKDM4ECYP3A4MAPT | |
| Flavonol SCHEMBL20246 | 0.85 | KDM4E (1.00) | MEN1KMT2AKDM4ECYP3A4MAPT | |
| Flavonol SCHEMBL29433939 | 0.85 | KDM4E (1.00) | MEN1KMT2AKDM4ECYP3A4MAPT | |
| Flavonol SCHEMBL1679068 | 0.85 | KDM4E (1.00) | MEN1KMT2AKDM4ECYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188144-B2 | In vitro preservation of living animal cells and compounds suitable for use in the preservation of living animal cells | ANTOXIS LIMITED (GB) | 2012-05-29 | — | — | US | disclosed |
| US-20110190514-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190514-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-7935714-B2 | Compositions for sleeping disorders | Bright Future Pharmaceutical Laboratories (HK) | 2011-05-03 | — | — | US | disclosed |
| US-7935714-B2 | Compositions for sleeping disorders | Bright Future Pharmaceutical Laboratories (HK) | 2011-05-03 | — | — | US | disclosed |
| US-20100267132-A1 | IN VITRO PRESERVATION OF LIVING ANIMAL CELLS AND COMPOUNDS SUITABLE FOR USE IN THE PRESERVATION OF LIVING ANIMAL CELLS | ANTOXIS LIMITED (GB) | 2010-10-21 | — | — | US | disclosed |
| US-20090258939-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. | 2009-10-15 | — | — | US | disclosed |
| US-20090258939-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. | 2009-10-15 | — | — | US | disclosed |
| US-7601754-B2 | Flavonoid compounds as therapeutic antioxidants | ANTOXIS LIMITED (GB) | 2009-10-13 | — | — | US | disclosed |
| US-7601754-B2 | Flavonoid compounds as therapeutic antioxidants | ANTOXIS LIMITED (GB) | 2009-10-13 | — | — | US | disclosed |
| WO-2009018350-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009018320-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| EP-1534698-B1 | FLAVONOID COMPOUNDS AS THERAPEUTIC ANTIOXIDANTS | ROWETT RES INST (GB) | 2007-09-19 | — | — | EP | disclosed |
| EP-1534698-B1 | FLAVONOID COMPOUNDS AS THERAPEUTIC ANTIOXIDANTS | ROWETT RES INST (GB) | 2007-09-19 | — | — | EP | disclosed |
| US-20060137207-A1 | Flavonoid compounds as therapeutic antioxidants | ANTOXIS LIMITED (GB) | 2006-06-29 | — | — | US | disclosed |
| EP-1578401-A2 | COMPOSITIONS AND METHODS FOR PROMOTING WEIGHT LOSS, THERMOGENESIS, APPETITE SUPPRESSION, LEAN MUSCLE MASS, INCREASING METABOLISM AND BOOSTING ENERGY LEVELS, AND USE AS A DIETARY SUPPLEMENT IN MAMMALS | RTC Research & Development, LLC. (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-1534698-A1 | FLAVONOID COMPOUNDS AS THERAPEUTIC ANTIOXIDANTS | The Rowett Research Institute (GB) | 2005-06-01 | — | — | EP | disclosed |
| US-20040077556-A1 | Compositions and methods for promoting weight loss, thermogenesis, appetite suppression, lean muscle mass, increasing metabolism and boosting energy levels, and use as a dietary supplement in mammals | RTC RESEARCH AND DEVELOPMENT, LLC | 2004-04-22 | — | — | US | disclosed |
| WO-2004007475-A1 | FLAVONOID COMPOUNDS AS THERAPEUTIC ANTIOXIDANTS | ROWETT RESEARCH INSTITUTE (GB) | 2004-01-22 | — | — | WO | disclosed |
| WO-2003090673-A2 | COMPOSITIONS AND METHODS FOR PROMOTING WEIGHT LOSS, THERMOGENESIS, APPETITE SUPPRESSION, LEAN MUSCLE MASS, INCREASING METABOLISM AND BOOSTING ENERGY LEVELS, AND USE AS A DIETARY SUPPLEMENT IN MAMMALS | RTC RESEARCH & DEVELOPMENT, LLC. (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258939-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | CYP11B2, CYP11B1, GLS2 | MEN1 535/4885KMT2A 4673/4885KDM4E 3466/4885 |
| US-20100267132-A1 | IN VITRO PRESERVATION OF LIVING ANIMAL CELLS AND COMPOUNDS SUITABLE FOR USE IN THE PRESERVATION OF LIVING ANIMAL CELLS | PIGS, AQP1, F12 | MEN1 731/4885KMT2A 3131/4885KDM4E 1441/4885 |
| US-20110190514-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | CYP11B2, CYP11B1, GLS2 | MEN1 535/4885KMT2A 4673/4885KDM4E 3466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.